To meet the needs for high-quality development of clinical trials under the new situation, further enhance the understanding and application of current regulations among personnel from sponsors, CROs, SMOs and clinical trial institutions, and effectively protect the safety and rights and interests of trial subjects, the 2026 Training Course on Quality Management of Clinical Trials for Drugs and Medical Devices was successfully held in Chengdu on June 12, 2026.

Jointly organized by Chengdu High-Tech Medical Association and The First Affiliated Hospital of Chengdu Medical College, and undertaken by the Regional GCP Alliance, the training attracted 600 participants from more than 20 medical institutions across the province. The attendees included project leaders, research physicians and nurses, ethics committee members, as well as key frontline staff from pharmaceutical enterprises.

PART 01 Opening Ceremony

The opening ceremony was presided over by Professor Zheng Lingli from The First Affiliated Hospital of Chengdu Medical College. Ai He, Vice President and Deputy Secretary-General of Chengdu High-Tech Medical Association, and Sun Yun, Party Secretary of The First Affiliated Hospital of Chengdu Medical College, attended the ceremony and delivered speeches.

Professor Zheng Lingli

The First Affiliated Hospital of Chengdu Medical College

Ai HeVice President & Deputy Secretary-General

Chengdu High-Tech Medical Association

Sun YunParty Secretary

he First Affiliated Hospital of Chengdu Medical College

PART 02 Core Topics on Clinical Trial Quality Management

The conference invited Professor Yu Qin from West China Second University Hospital of Sichuan University, Professor Feng Yanyan from Chengdu Second People's Hospital, Professor Chen Xia from Chongqing University Cancer Hospital, and Manager Zhang Longyin from Jiangsu Hengrui Medicine Co., Ltd. to deliver lectures.

Based on regulatory frameworks and practical experience, the expert team elaborated on five core topics tailored to the practical difficulties in the industry with in-depth interpretations and sharing from multiple perspectives:

1.Interpretation of the revised Good Clinical Practice for Drug Clinical Trials, including a comparative analysis between the new and old versions for in-depth learning.

2Analysis of ideas for building clinical trial research teams and solutions to common team development bottlenecks.

3.Introduction to the construction approaches and practical application of clinical trial information platforms.

4.Summary of existing difficulties in ethical review and provision of standardized response plans.

5.Discussion on clinical trial cooperation models between hospitals and enterprises, as well as exchanges on the implementation of collaborative innovation.

Distinguished Speakers

Professor Yu Qin

West China Second University Hospital, Sichuan University

Manager Zhang Longyin

Jiangsu Hengrui Medicine Co., Ltd.

Professor Chen Xia

Chongqing University Cancer Hospital

Professor Feng Yanyan

Chengdu Second People's Hospital

Host Highlights

PART 03 Conference Summary

This targeted and highly practical training has effectively strengthened participants' awareness of regulatory compliance and professional capabilities. Going forward, we will fully translate the training outcomes into practice, improve the quality control system for clinical trials, and standardize the whole workflow covering ethical review, team management, IT system development and hospital-enterprise cooperation. It will help advance drug and medical device clinical trials in a safe, compliant and high-quality manner.